27.02.2014 Views

Brazilian_Patent_Reform

Brazilian_Patent_Reform

Brazilian_Patent_Reform

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

147<br />

character. Article 240, for instance, which establishes the purpose of the <strong>Brazilian</strong> <strong>Patent</strong><br />

Office, and Article 241, authorizing the creation of special intellectual property courts,<br />

are not mere transitional provisions, despite being included under this title.<br />

In order to avoid biased interpretation, we propose a legislative alteration aimed at making<br />

evident that ANVISA’s prior consent is applicable to all types of patent applications in<br />

the pharmaceutical field and not just those filed under the pipeline mechanism.<br />

8.3 ANVISA’s prior consent and its<br />

relevance to public health<br />

In this section we deal with ANVISA’s participation on applications for the grant of<br />

pharmaceutical patents in order to make evident the importance of this participation<br />

for the protection of public health.<br />

An important study conducted by ANVISA makes a qualitative analysis of the decisions<br />

issued in the exercise of prior consent for the period between 2001 and 2009 225 and<br />

shows how the participation of the Agency in patent grant procedures has been proving<br />

relevant not only to avoid the grant of inappropriate patents but also to increase the<br />

quality of granted patents. It is important to remember that ANVISA only analyzed<br />

patent applications after examination by the <strong>Brazilian</strong> <strong>Patent</strong> Office and only when the<br />

latter considered the application ready for granting – as the Inter-ministerial Working<br />

Group had not yet gathered to deliberate about the procedures.<br />

Between 2001 and 2009 (until October), ANVISA analyzed 1,346 patent applications.<br />

Out of those applications: i) 988 were granted consent; ii) 119 were denied consent; iii)<br />

90 were barred by the <strong>Brazilian</strong> <strong>Patent</strong> Office after ANVISA’s examination and iv) 149<br />

were in other situations as of the conclusion of the study (such as waiting for ANVISA’s<br />

examination or for the fulfillment of requirements by the applicant). The main reasons<br />

for denial of consent by ANVISA are shown in the following table.<br />

225 Coordenação de Propriedade Intelectual – COOPI/GGMED/ANVISA. Technical opinion concerning Bill<br />

No. 3.709/2008. November 25, 2009. Available at:: http://www2.camara.gov.br/atividade-legislativa/<br />

comissoes/comissoes-permanentes/cdeic/audiencias/audiencia-publica-24-11-2009/Parecer%20<br />

Tecnico%20relativo%20ao%20PL3709-2008.pdf/at_download/file.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!